Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05629442 · ClinicalTrials.gov registry record
ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
A clinical trial, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- 60
- Enrollment target
NCT05629442: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT05629442 is a clinical trial that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05629442 has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- 60 participants
- Enrollment target
Study Summary
This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy. This research study involves the collection of data and biospecimens (blood and tissue) to see if the presence of circulating tumor DNA (genetic material) ctDNA will help monitor rectal cancer more closely and potentially detect a recurrence before routine scans, performed per standard of care C2i Genomics, a biotechnology company, and the Spier Foundation are supporting this research study by providing funding for the study.
Interventions
- OTHER ctDNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2030-06 |
What is known before NCT05629442 opens enrollment
NCT05629442 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ctDNA is the first listed.
NCT05629442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05629442 about?
NCT05629442 is a clinical study titled "ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer". This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy. This research study involves the collection of data and biospecimens (blood and tissue) to see if the presence of circulating tumor DNA (gene...
What is the current status of trial NCT05629442?
This trial is currently not yet recruiting. The enrollment target is 60 participants. The study started on 2026-10-01. Estimated completion is 2030-06.
What interventions are being tested in trial NCT05629442?
The interventions under investigation include: ctDNA (OTHER).
Who is sponsoring clinical trial NCT05629442?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI